10 new oncology trials approved in Europe
 |
Oncology Hero |
10 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week.
Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study MeetURO and FICOG trial
| Sponsor: Fondazione IRCCS Istituto Nazionale Dei Tumori | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestBiFAST: A phase II trial evaluating fixed dose and faster ramp-up of epcoritamab with lenalidomide for 3L relapse/refractory large B-cell lymphoma after CAR T-cells therapy in 2nd line
| Sponsor: LYSARC | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestHyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma
| Sponsor: Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator’s choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy
| Sponsor: Universitaetsklinikum Heidelberg AöR | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).
| Sponsor: AstraZeneca AB | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestPRadR 2 - A single center, open-label, Phase I study evaluating 161Tb-PSMA therapy in adult patients with metastatic clear cell renal cell carcinoma
| Sponsor: Centre Leon Berard | Phase: 1 |
Interested in offering this trial to suitable patients?
Register Investigator InterestPerioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial
| Sponsor: UZ Leuven | Phase: 1, 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestHOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
| Sponsor: Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase II, single-arm trial on the addition of the DLL3xCD3 bispecific T-cell engager obrixtamig (BI 764532) to standard-of-care platinum-based first-line treatment of advanced large-cell neuroendocrine carcinoma of the lung
| Sponsor: Technische Universitaet Dresden | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER
| Sponsor: F. Hoffmann-La Roche AG | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestOncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
In partnership with Oncology Updates — Aug 26 to Sep 2025 September delivered practice-relevant oncology updates worldwide — guideline shifts, pivotal trial readouts, new approvals, and high-impact AI tools. Below is a concise, clinician-first roundup. 🎗️ 🩺Lung cancer ESMO issues NSCLC guideline for early & locally advanced disease New recommendations standardize biomarker-driven multimodality care in stage I–III NSCLC, including integration of IO/targeted therapy in pathways. Read more...
Oncology Updates — August 2025 August 2025 delivered practice-relevant oncology updates worldwide — fresh guideline shifts, pivotal trial readouts, new approvals, diagnostics/devices, and high-impact AI tools. Below is a concise, clinician-first roundup, capped with a focused deep dive on the updated ASCO NSCLC guidelines. 🎗️ 💼 Earn for training the next generation of AI tools Medical Expert Hourly contract · Remote · $130–$180 per hour Apply here Physicians, Pathologists (Health Care and...
Regeneron Acquires 23andMe Research Division for $256M in Bankruptcy Auction Context: As 23andMe navigates Chapter 11 proceedings, key assets tied to its vast genomic database and pharma partnerships have drawn industry attention. What's New? Regeneron has secured a $256 million deal to acquire 23andMe’s therapeutics subsidiary, aiming to leverage the platform’s extensive genotypic and phenotypic data to fuel its precision medicine pipeline. Why it Matters? This acquisition gives Regeneron a...